UFIS-SWE-IG
0.1.0 - ci-build

UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions

Example Bundle: Triolif-Orange-Lozenge-SE-AJ-MPD-BBDL

Triolif Apelsin Sugtablett

MPID: SE-xxxxxxxxx-00049613
EURDID: 206

Full name: Triolif Apelsin Sugtablett

- Invented Name Part: Triolif

- Flavour part: Apelsin

- Pharmaceutical dose form part: Sugtablett

Name usage: Swedish (Kingdom of Sweden)

Authorised dose form: Lozenge

Legal status of supply: Medicinal product not subject to medical prescription

Domain: Human use

Resource status: Current

Product classification:

  • 100000098045 various

Marketing Authorisation 1 of 1

Authorisation number: 49613

Region: Kingdom of Sweden

Marketing authorisation holder: Karo Pharma AS

Identifier:

  • LOC-100017033

Status: Valid (2015-05-07)

Package 1 of 1

PCID:

Description:
Blister, 24 tabletter

Marketing status:

  • Kingdom of Sweden: Marketed

Pack size:

  • 24 Lozenge

Package: 1 Box (Cardboard)

Containing:

Package: 2 Blister (Aluminium) (PolyVinyl Chloride) (PolyVinylidene Chloride)

Containing: 12 Lozenge

Manufactured Item

Dose form: Lozenge

Unit of presentation: Lozenge

Ingredient

Role: Active

Substance: Lidocaine hydrochloride monohydrate

Presentation strength: 2.13 milligram(s) / 1 Lozenge

Reference strength:
Lidocaine 1.62 milligram(s) / 1 Lozenge

Reference strength:
Lidocaine hydrochloride 2 milligram(s) / 1 Lozenge

Ingredient

Role: Active

Substance: Amylmetacresol

Presentation strength: 0.6 milligram(s) / 1 Lozenge

Reference strength:
Amylmetacresol 0.6 milligram(s) / 1 Lozenge

Ingredient

Role: Active

Substance: 2,4 dichlorobenzyl alcohol

Presentation strength: 1.2 milligram(s) / 1 Lozenge

Reference strength:
2,4 dichlorobenzyl alcohol 1.2 milligram(s) / 1 Lozenge

Administrable Product (1 of 1)

Dose form: Lozenge

Unit of presentation:

Route of administration:

  • Oropharyngeal use
  • Oromucosal use

Ingredients:

Ingredient

Role: Active

Substance: Lidocaine hydrochloride monohydrate

Presentation strength: 2.13 milligram(s) / 1 Lozenge

Reference strength:
Lidocaine 1.62 milligram(s) / 1 Lozenge

Reference strength:
Lidocaine hydrochloride 2 milligram(s) / 1 Lozenge

Ingredient

Role: Active

Substance: Amylmetacresol

Presentation strength: 0.6 milligram(s) / 1 Lozenge

Reference strength:
Amylmetacresol 0.6 milligram(s) / 1 Lozenge

Ingredient

Role: Active

Substance: 2,4 dichlorobenzyl alcohol

Presentation strength: 1.2 milligram(s) / 1 Lozenge

Reference strength:
2,4 dichlorobenzyl alcohol 1.2 milligram(s) / 1 Lozenge